|
The convergence of socioeconomic and
technology factors – the growing emphasis on drug self-administration for
chronic conditions, the expected acceleration in protein- and
peptide-based therapeutics, the availability of innovative dry powder
inhalation devices with unique device designs - is driving interest in
pulmonary drug delivery technology and devices as an alternative to oral
and parenteral routes of administration. While several approaches for
delivering active substances to, and systematically via, the lungs compete
in this space, recent advances and investment in powder formulations,
particle engineering, and device architecture have positioned dry powder
inhalers to take full advantage of these trends. The report includes
comprehensive assessments of current and future dry powder inhalation, dry
powder inhalation technology, industry data and forecasts, device and
particle technology profiles, key alliances and partnerships, and detailed
analysis of design and economic factors. The report has been organized and
written to provide pharmaceutical professionals, drug delivery market
participants, and supply chain companies with all of the information
necessary to understand the growing impact of dry powder inhalers on drug
design and development, therapeutic protocols, and healthcare economics.
Publication Date: July 2009
|
